CA2759442C - Galactooligosaccharide for use in prevention of intestinal inflammatory disorder - Google Patents

Galactooligosaccharide for use in prevention of intestinal inflammatory disorder Download PDF

Info

Publication number
CA2759442C
CA2759442C CA2759442A CA2759442A CA2759442C CA 2759442 C CA2759442 C CA 2759442C CA 2759442 A CA2759442 A CA 2759442A CA 2759442 A CA2759442 A CA 2759442A CA 2759442 C CA2759442 C CA 2759442C
Authority
CA
Canada
Prior art keywords
gal
beta
galactooligosaccharide
cells
gos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2759442A
Other languages
English (en)
French (fr)
Other versions
CA2759442A1 (en
Inventor
Georgios Tzortzis
Jelena Vulevic
Francesco Attanasio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clasado Ltd
Original Assignee
Clasado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40774842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2759442(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Clasado Inc filed Critical Clasado Inc
Publication of CA2759442A1 publication Critical patent/CA2759442A1/en
Application granted granted Critical
Publication of CA2759442C publication Critical patent/CA2759442C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
CA2759442A 2009-04-23 2010-04-23 Galactooligosaccharide for use in prevention of intestinal inflammatory disorder Active CA2759442C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0906983.2A GB0906983D0 (en) 2009-04-23 2009-04-23 Novel use
GB0906983.2 2009-04-23
GB0920784.6 2009-11-27
GBGB0920784.6A GB0920784D0 (en) 2009-04-23 2009-11-27 Novel use
PCT/GB2010/050659 WO2010122344A1 (en) 2009-04-23 2010-04-23 Novel use

Publications (2)

Publication Number Publication Date
CA2759442A1 CA2759442A1 (en) 2010-10-28
CA2759442C true CA2759442C (en) 2016-01-19

Family

ID=40774842

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2759442A Active CA2759442C (en) 2009-04-23 2010-04-23 Galactooligosaccharide for use in prevention of intestinal inflammatory disorder

Country Status (25)

Country Link
US (1) US20120058972A1 (https=)
EP (1) EP2421541B1 (https=)
JP (1) JP2012524770A (https=)
KR (1) KR20110138416A (https=)
CN (1) CN102427818A (https=)
AU (1) AU2010240642B2 (https=)
BR (1) BRPI1015091A2 (https=)
CA (1) CA2759442C (https=)
CY (1) CY1120597T1 (https=)
DK (1) DK2421541T3 (https=)
ES (1) ES2688786T3 (https=)
GB (3) GB0906983D0 (https=)
HU (1) HUE040451T2 (https=)
IL (1) IL215855A0 (https=)
MX (1) MX341308B (https=)
MY (1) MY151104A (https=)
NZ (1) NZ595969A (https=)
PL (1) PL2421541T3 (https=)
PT (1) PT2421541T (https=)
RU (1) RU2530567C2 (https=)
SG (1) SG175313A1 (https=)
TR (1) TR201810868T4 (https=)
UA (1) UA106491C2 (https=)
WO (1) WO2010122344A1 (https=)
ZA (1) ZA201107821B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
DK2734210T3 (en) 2011-07-22 2018-01-22 Abbott Lab GALACTOOLIGOSACCHARIDES FOR THE PREVENTION OF DAMAGE TO AND / OR PROMOTION OF HEALING OF THE MAVE GAS CHANNEL
CN103716787B (zh) 2012-09-29 2020-06-23 北京三星通信技术研究有限公司 一种支持对家用基站进行验证的方法
CN107771083A (zh) * 2015-04-23 2018-03-06 卡莱多生物科技有限公司 聚糖治疗剂和治疗方法
CN107158011A (zh) * 2017-05-25 2017-09-15 浙江大学 低聚半乳糖在制备治疗肠道疾病的药物中的用途
US12508273B2 (en) 2019-05-15 2025-12-30 N.V. Nutricia Beta-1,3′-galactosyllactose for the treatment of gut barrier function diseases
US20240277739A1 (en) * 2021-07-01 2024-08-22 N.V. Nutricia Nutritonal compositions for gut barrier function
KR102453998B1 (ko) * 2022-01-07 2022-10-14 (주)네오크레마 갈락토올리고당을 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물
GB2619977A (en) * 2022-06-24 2023-12-27 Clasado Res Services Limited Compositions and uses thereof
GB2623336A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof
GB2623335A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
GB0315266D0 (en) * 2003-06-30 2003-08-06 Clasado Inc Novel galactooligosaccharide composition and the preparation thereof
ATE360682T1 (de) * 2003-06-30 2007-05-15 Clasado Inc Neue galactooligosaccharidzusammensetzung und herstellung davon
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
EP1887017A1 (en) * 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
GB0809921D0 (en) 2008-05-30 2008-07-09 Clasado Inc Product and process therefor

Also Published As

Publication number Publication date
PT2421541T (pt) 2018-10-15
RU2011147390A (ru) 2013-05-27
SG175313A1 (en) 2011-11-28
MX2011011159A (es) 2011-11-07
CN102427818A (zh) 2012-04-25
IL215855A0 (en) 2012-01-31
WO2010122344A1 (en) 2010-10-28
GB2482817B (en) 2014-02-26
MX341308B (es) 2016-08-12
CY1120597T1 (el) 2019-12-11
CA2759442A1 (en) 2010-10-28
NZ595969A (en) 2013-03-28
DK2421541T3 (en) 2018-09-24
EP2421541B1 (en) 2018-07-11
JP2012524770A (ja) 2012-10-18
BRPI1015091A2 (pt) 2016-04-26
TR201810868T4 (tr) 2018-08-27
AU2010240642A1 (en) 2011-11-10
KR20110138416A (ko) 2011-12-27
ZA201107821B (en) 2012-07-25
GB201120030D0 (en) 2012-01-04
US20120058972A1 (en) 2012-03-08
AU2010240642B2 (en) 2013-03-14
HUE040451T2 (hu) 2019-03-28
MY151104A (en) 2014-04-15
EP2421541A1 (en) 2012-02-29
GB2482817A (en) 2012-02-15
GB0906983D0 (en) 2009-06-03
RU2530567C2 (ru) 2014-10-10
UA106491C2 (uk) 2014-09-10
GB0920784D0 (en) 2010-01-13
ES2688786T3 (es) 2018-11-06
PL2421541T3 (pl) 2018-11-30

Similar Documents

Publication Publication Date Title
CA2759442C (en) Galactooligosaccharide for use in prevention of intestinal inflammatory disorder
CA2724766A1 (en) Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
AU2015262214B2 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from Akkermansia muciniphila bacteria
US20240309408A1 (en) Methods of Use of Oligosaccharide Compositions for Modulating Microbiota and their Metabolic Products, and as Therapeutics for Health Applications
JP2021063079A (ja) グリカン治療剤及びその関連方法
CN102670662A (zh) 糖醛酸和益生菌
CN107771083A (zh) 聚糖治疗剂和治疗方法
WO2011005681A1 (en) Inhibiting inflammation with milk oligosaccharides
NZ264517A (en) An antiulcer agent comprising fucoidan as adhesion inhibitor
Ambrogi et al. Bifidobacterial β-galactosidase-mediated production of galacto-oligosaccharides: structural and preliminary functional assessments
US20250288601A1 (en) Methods for treating urogenital health conditions
Macfarlane et al. Food and the large intestine
CN101372679B (zh) 一种双歧双歧杆菌菌株及其使用方法
Ambrogi et al. Bifidobacterial ß-galactosidase-mediated production of galacto-oligosaccharides: structural and preliminary functional assessments
US20140212494A1 (en) Methods of Improving Digestive Health
Spence et al. Digestive Disease Week 2020
Fellin Spence et al. Digestive Disease Week 2020. Virtual Meeting-May 2020
TW202333752A (zh) 以外多醣治療睡眠障礙之方法
KR20240053740A (ko) 인간 모유 올리고당 및 베타-글루칸이 포함된 장기능 개선용 조성물
Manchanayake The Impact of Gut Microbiota on Host Obesity. J Gastrointest Dig Syst 9: 591. doi: 10.4172/2161-069X. 1000591 Page 2 of 8 J Gastrointest Dig Syst, an open access journal ISSN: 2161-069X Volume 9• Issue 1• 1000591
Ambrogi et al. β-Galactosidase-Mediated Production of Galacto-Oligosaccharides: Structural and Preliminary Functional Assessments
D’AURIA et al. Ph. D. PROGRAM IN “PHARMACEUTICAL SCIENCES” Cycle XXVIII

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130215

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250415

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250415

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260413

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260413